Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.37 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.37 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507541 | 0.89 | SCN9A (0.44) | FLT3ARPRKAA2 | |
| Hydrochloric Acid SCHEMBL1081664 | 0.89 | SCN9A (0.43) | FLT3ARPRKAA2 | |
| SCHEMBL12199818 | 0.86 | PRKAA2 (0.43) | ARMAPTHRH3PRKAA2 | |
| SCHEMBL12199795 | 0.86 | GPR119 (0.50) | MAPTHRH3 | |
| SCHEMBL4403480 | 0.85 | HRH3 (0.41) | HPGDSARSMYD3HRH3MAOA | |
| SCHEMBL12199804 | 0.84 | DRD4 (0.44) | FLT3PRKAA2MAOAMAOB | |
| SCHEMBL12199809 | 0.84 | PRKAA2 (0.52) | PRKAA2 | |
| SCHEMBL12199813 | 0.84 | PRKAA2 (0.55) | ARPRKAA2 | |
| SCHEMBL12199800 | 0.83 | MAOA (0.53) | PRKAA2MAOAMAOB | |
| SCHEMBL4405686 | 0.83 | MAOB (0.43) | ARSMYD3MAPTHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150232451-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2015-08-20 | — | — | US | disclosed |
| US-9062052-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150011582-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2015-01-08 | — | — | US | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | MIDCAP FINANCIAL TRUST | 2014-10-30 | — | — | US | disclosed |
| US-8871770-B2 | Carboxamide compounds and methods for using the same | MIDCAP FINANCIAL TRUST | 2014-10-28 | — | — | US | disclosed |
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8785449-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140148467-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | FLT3 1770/4885HPGDS 3594/4885AR 3066/4885 |
| US-20140148467-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | FLT3 699/4885HPGDS 2640/4885AR 571/4885 |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | FLT3 1770/4885HPGDS 3594/4885AR 3066/4885 |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | FLT3 699/4885HPGDS 2640/4885AR 571/4885 |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | FLT3 699/4885HPGDS 2640/4885AR 571/4885 |
| US-20150232451-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | FLT3 699/4885HPGDS 2640/4885AR 571/4885 |
| US-20150011582-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | FLT3 699/4885HPGDS 2640/4885AR 571/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | FLT3 2108/4885HPGDS 2551/4885AR 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.